TCRX
Tscan Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$60.88M
P/E Ratio
—
EPS
$-1.00
Beta
1.01
52W High
$2.57
52W Low
$0.88
50-Day MA
$1.04
200-Day MA
$1.43
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Tscan Therapeutics Inc
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology firm that specializes in advancing immunotherapy through its proprietary T cell receptor (TCR) discovery platform, targeting specific cancer antigens to offer precision medicine solutions in oncology. The company is focused on developing innovative TCR-based therapeutics aimed at translating scientific advancements into effective treatment options for various cancers and diseases, ultimately improving patient outcomes. With a strong therapeutic pipeline and a comprehensive intellectual property portfolio, Tscan Therapeutics is well-positioned to become a leader in the rapidly evolving landscape of T cell-based therapies.
Fundamentals
| Revenue (TTM) | $10.32M |
| Gross Profit (TTM) | $-102.22M |
| EBITDA | $-130.95M |
| Operating Margin | -852.00% |
| Return on Equity | -71.30% |
| Return on Assets | -27.90% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $2.16 |
| Price-to-Book | 0.47 |
| Price-to-Sales (TTM) | 5.90 |
| EV/Revenue | 0.0606 |
| EV/EBITDA | 0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 286.00% |
| Shares Outstanding | $52.63M |
| Float | $47.27M |
| % Insiders | 0.23% |
| % Institutions | 65.76% |
Historical Volatility
HV 10-Day
57.80%
HV 20-Day
51.39%
HV 30-Day
60.95%
HV 60-Day
59.89%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($6.00 target)
1
Strong Buy4
Buy1
HoldData last updated: 4/9/2026